Categories
World News

For China’s Single Moms, a Highway to Recognition Paved With False Begins

For a few wonderful weeks, Zou Xiaoqi, a single mother in Shanghai, felt accepted by her government.

After giving birth in 2017, Ms. Zou, a financial clerk, went to court to question Shanghai’s policy of granting maternity benefits only to married women. She had little success and lost one lawsuit and two appeals. Then, earlier this year, the city suddenly dropped its marriage obligation. In March, a jubilant Ms. Zou received a performance check on her bank account.

She had barely started partying when the government reintroduced policy a few weeks later. Unmarried women were again not entitled to government payments for medical care and paid vacation.

“I always knew there was this possibility,” said Ms. Zou, 45 years old. “If you can get me to return the money, I will probably return it.”

The Shanghai authorities’ flip-flop reflects a broader view in China of longstanding attitudes towards family and gender.

Chinese law does not specifically prohibit single women from giving birth. However, official family planning guidelines only mention married couples, and local officials have long provided benefits based on these provisions. Only Guangdong Province, which borders Hong Kong, allows unmarried women to apply for maternity insurance. In many places women still face fines or other punishments for childbirth out of wedlock.

But as China’s birthrate has plummeted in recent years and a new generation of women embraced feminist ideals, these traditional values ​​have come under increasing pressure. Now a small but determined group of women are demanding guaranteed maternity benefits regardless of marital status – and, more generally, recognition of their right to make their own reproductive choices.

The U-turn in Shanghai, however, highlights the challenges facing feminists in China, where women face deeply ingrained discrimination and a government that is suspicious of activism.

It also shows the authorities’ reluctance to give up decades of control over family planning, even in the face of demographic pressures. The ruling Communist Party announced Monday that it would end its two-child policy, which allows couples to have three children in the hope of reversing a falling birth rate. However, single mothers remain unrecognized.

“There has never been a change in the policy,” said a Shanghai maternity hotline agent when he was reached by phone. “Single mothers never met the requirements.”

Ms. Zou, who found out she was pregnant after breaking up with her boyfriend, said she would continue to fight for recognition even though she didn’t need the money.

“This is about the right to vote,” she said. Currently, when an unmarried woman becomes pregnant, “You can either get married or have an abortion. Why not give people the right to a third choice? “

As education levels have risen in recent years, more and more Chinese women have refused marriage, childbirth, or both. According to government statistics, only 8.1 million couples got married in 2020, the lowest number since 2003.

With the rejection of marriage, the recognition of single mothers has increased. There are no official statistics on single mothers, but a 2018 report by the state-sponsored All-China Women’s Federation estimates that there will be at least 19.4 million single mothers in 2020. These included widowed and divorced women.

When Zhang A Lan, a 30-year-old filmmaker, grew up in Central Hebei Province, unmarried mothers were viewed as defiled and sinful, she said. When she decided to give birth without getting married two years ago, it was common for people on social media to question these old stereotypes.

“Marriage is obviously not a prerequisite for childbirth,” said Ms. Zhang, who gave birth to a boy last year.

Yet many women described a persistent gap between attitudes on the Internet and in reality.

Many Chinese are still concerned about the financial burden and social stigma that single mothers face, said Dong Xiaoying, a Guangzhou lawyer who advocates the rights of single mothers and gay couples. Lesbians are also often denied maternity rights because China does not recognize same-sex unions.

Ms. Dong, who wants to have a child out of wedlock herself, said her parents found the decision incomprehensible.

“It’s a bit like getting out of the closet,” said Ms. Dong, 32. “There’s still a lot of pressure.”

However, the biggest obstacles are official.

The authorities have taken some measures to start recognizing the reproductive rights of single women. A representative of the National People’s Congress, China’s legislature, has for years put forward proposals to improve the rights of unmarried women. While authorities have shut down other feminist groups, those who support unmarried mothers have largely escaped control.

The easier contact with authorities may be due, at least in part, to the fact that women’s goals are aligned with national priorities.

China’s birth rate has declined in recent years after decades of one-child policies severely reduced the number of women of childbearing age. Recognizing the threat to economic growth, the government has begun pushing women to have more children. On Monday, she announced that couples would be allowed to have three children. The government’s latest five-year plan, published last year, promised a more “inclusive” birth policy and raised hopes for recognition of unmarried mothers.

A state outlet was recently mentioned in a headline about the original relaxation of politics in Shanghai: “More and more Chinese cities are offering maternity insurance to unmarried mothers in the demographic crisis.”

But the obvious support only goes so far, said Ms. Dong. Far from promoting women’s empowerment, the authorities have recently attempted to pull women out of the workforce and return to traditional gender roles – the opposite of what single motherhood would allow. “From a governance point of view, they don’t really want to open up completely,” she said.

The National Health Commission emphasized this year that family planning is the responsibility of “husbands and wives together”. In January, the Commission rejected a proposal to open up egg freezing to single women, citing ethical and health concerns.

Open rejection of gender norms can still lead to reprisals. Last month, Douban, a social media site, shut down several popular forums where women discussed their desire not to marry or have children. Site moderators accused the groups of “extremism”, according to group administrators.

Shanghai’s U-turn was the clearest example of the authorities’ mixed message on the reproductive rights of unmarried women.

When the city appeared to be expanding maternity benefits earlier this year, officials never specifically mentioned unmarried women. Their announcement simply said that a “family planning review” that required a marriage certificate would no longer be conducted.

In April women were again asked for their marriage certificates when applying online.

“The local administrators don’t want to take responsibility,” said Ms. Dong. “No higher national authority has said that these family planning rules can be relaxed, so they don’t dare to open that window.”

Many women hope that pressures from an increasingly vocal public will make such regulations untenable.

32-year-old Teresa Xu saw this postponement firsthand in 2019 when she filed a lawsuit against China’s ban on freezing eggs for single women. At first, the judge treated her like a “naive little girl,” she said. But when her case found support on social media, officials became more respectful.

Even so, her case is still pending and officials have not given her an update in over a year. Ms. Xu said she was confident in the long run.

“There’s no way of predicting what they’re going to do in the next two or three years,” she said. “But I think there are some things that cannot be denied when it comes to the development and desires of society. There is no way to reverse this trend. “

Joy Dong contributed to the research.

Categories
Health

Single dose of vaccine can virtually halve transmission

A nurse, Cindy Mendez, wearing a protective mask, holds a syringe containing a dose of Pfizer-BioNTech COVID-19 vaccine during the coronavirus disease (COVID-19) pandemic at NYC Health + Hospitals Harlem Hospital in the Manhattan neighborhood of New York City. New York, February 25, 2021.

Jeenah Moon | Reuters

LONDON – A single dose of coronavirus vaccine can cut transmission within a household by up to half, a study by Public Health England found.

People who became infected with the coronavirus three weeks after receiving a single dose of the Pfizer-BioNTech or AstraZeneca-University of Oxford vaccine were between 38% and 49% less likely to pass the virus on to their household contacts than those who weren’t vaccinated, the PHE found -Study.

Protection was observed approximately 14 days after vaccination with similar levels of protection regardless of the age of the cases or contacts.

That protection comes on top of the reduced risk that a vaccinated person will develop symptomatic infection in the first place, which is around 60% to 65% – four weeks after a dose of either vaccine, according to PHE. Both doses of a coronavirus vaccine (the delay between doses is up to 12 weeks in the UK) offer even greater protection against Covid infections.

UK Health Secretary Matt Hancock hailed the study’s results as “great news”. “We already know that vaccines save lives, and this study is the most comprehensive real-world data to show that they also reduce the transmission of this deadly virus.”

“It further underscores that vaccines are the best way out of this pandemic as they protect you and potentially prevent you from unwittingly infecting anyone in your household.”

“I urge everyone to get their vaccines as soon as they are eligible and make sure you get your second dose to ensure the best possible protection,” he added.

Both Pfizer BioNTech and AstraZeneca vaccines are used extensively in the UK, and the Moderna vaccine is now also included in the immunization program.

The introduction of vaccines was a tremendous success in the UK and a silver lining after the devastation of the pandemic that has caused over 127,000 deaths in the country to date.

In the UK, cases, hospitalizations and deaths have fallen dramatically since it was launched in December, along with strict lockdown measures. To date, nearly 34 million adults in the UK have had a first dose of vaccine and over 13 million two doses, government data shows.

The PHE study found that households are at high risk for transmission and provide early evidence of the effects of vaccines on preventing transmission. Similar results might be expected in other settings with similar transmission risks, for example in shared apartments and prisons.

The study, which is a pre-print that has not yet been peer-reviewed, included over 57,000 contacts from 24,000 households who had a laboratory-confirmed coronavirus case vaccinated, compared to nearly 1 million contacts from unvaccinated cases.

By linking case and household contact data with vaccination status, the study compared the probability of transmission for a vaccinated case with a non-vaccinated one.

PHE is also conducting separate studies on the effects of vaccination on transmission in the broader population.

Categories
Health

Single dose cuts an infection charge by 65%, examine finds

James Shaw, 82, receives Oxford University / AstraZeneca COVID-19 vaccine from advanced nurse Justine Williams on January 4, 2021 at Lochee Health Center in Dundee, Scotland, UK.

Andy Buchanan | Reuters

LONDON – A single dose of the Covid-19 vaccine from Oxford-AstraZeneca or Pfizer-BioNTech drastically reduces the risk of infection in adults of all ages, British researchers have found.

Two studies published on Friday analyzed more than 1.6 million nasal and throat swabs from 373,402 people between December and April. The data was collected as part of the ongoing Covid-19 infection survey carried out by Oxford University, the UK Office for National Statistics and the UK Department of Health and Welfare.

The researchers found that 21 days after a single dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccine, new Covid infections – both symptomatic and asymptomatic – had decreased by 65%.

Symptomatic infections decreased by 74% three weeks after a single dose of either vaccine, while asymptomatic cases decreased by 57%, the data showed.

A second dose of vaccine reduced the overall infection rate by 70%, reducing symptomatic Covid infections by 90% and asymptomatic cases of the virus by 49%.

The researchers compared these effects to the natural immunity obtained from infection with the virus.

However, they warned that the fact that vaccinated people could still be infected – even if those infections were mostly asymptomatic – meant “transmission possible”.

The study found that vaccines had a similar effect in reducing infection rates in adults of all ages. Their ability to reduce infection was also similar, regardless of whether the participants had long-term health conditions or not.

What about antibody resistance?

The scientists also looked at the effects of Covid vaccinations on participants’ antibody levels.

They found that older adults – especially those over 60 – who had never been infected with Covid had a lower immune response to a single dose of vaccine than those who had previously been infected with the virus.

Antibody responses to two doses of the Pfizer BioNTech vaccine were high in all age groups. The data showed that older adults were able to achieve antibody levels similar to those who received a vaccine dose after a previous Covid infection.

Too few people in the UK had received two doses of the Oxford AstraZeneca vaccine for researchers to assess the effects on antibody response. However, it was found that immune responses to a first dose differed between the Oxford AstraZeneca vaccine and the Pfizer BioNTech vaccine.

Antibody levels rose more slowly after a single dose of the Oxford-AstraZeneca vaccine than after the Pfizer-BioNTech alternative. However, after a dose of the latter, antibody levels fell more rapidly, especially in older adults, so patients achieved antibody levels similar to those seen after an initial dose of the Oxford-AstraZeneca vaccine.

Although immune responses differed between age groups, the scientists emphasized that there was no group that did not respond to either vaccine. However, a small number of people – less than 5% – had poor immune responses to both vaccines.

Important to get the second dose

The Oxford-AstraZeneca vaccine has been approved for use in the UK, India and several other countries, but has been temporarily suspended in some markets amid concerns that it could be linked to rare blood clots. Global health officials have stated that the benefits of giving the vaccine continue to outweigh the risks.

The WHO recommends an interval of eight to 12 weeks between the first and second dose of the Oxford AstraZeneca vaccine.

The Pfizer BioNTech vaccine is also given in several countries, including the United States. The U.S. Centers for Disease Control and Prevention recommends receiving a second dose of the vaccine three weeks after the first.

In February, the UK started a study to see if mixing doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines could be effective.

Sarah Walker, professor of medical statistics and epidemiology at Oxford University and chief investigator and academic director of the Covid-19 infection survey, said Friday that scientists are still not sure how strong and how long an antibody response is. was needed for long-term protection against Covid.

David Eyre, associate professor at Oxford University’s Big Data Institute, added that the results released on Friday highlighted the importance of a second dose of vaccine for increased protection.

Categories
Business

CDC examine reveals single dose of Pfizer or Moderna Covid vaccines was 80% efficient

According to a new study by the Centers for Disease Control and Prevention of vaccinated health care workers, a single dose of the Covid-19 vaccine from Pfizer or Moderna was 80% effective in preventing coronavirus infections.

The effectiveness of the partial immunization was noted two weeks after the first dose, according to the CDC, which studied nearly 4,000 health care workers, first responders and frontline workers between December 14 and March 13, according to other key study staff, which began on Monday had no prior laboratory documentation of the Covid-19 infection.

Two doses are better than one, federal health officials said, adding that the vaccines’ effectiveness rose to 90% two weeks after the second dose.

“These results show that approved mRNA-COVID-19 vaccines in adults of working age effectively prevent SARS-CoV-2 infection under real conditions, regardless of symptom status,” wrote the US agency in the study. “The COVID-19 vaccination is recommended to all entitled persons.”

The new CDC results should back up arguments by some health experts and health officials that the US should give Americans only one dose of vaccines as a priority before moving on to a second dose, accelerating the pace of vaccination across the country.

The CDC results were released just minutes before the press conference by the agency’s director, Dr. Rochelle Walensky, the hospital also released as vaccinations nationwide expedite.

Unlike the Johnson & Johnson vaccine, which requires one dose, the Pfizer and Moderna vaccines require two vaccinations three to four weeks apart. The Chief Medical Officer of the White House, Dr. Anthony Fauci, has said repeatedly over the past few months that the US should stick to the two-dose regime.

Dr. Paul Offit, a voting member of the FDA’s Advisory Committee on Vaccines and Related Biological Products who reviewed both Pfizer’s and Moderna’s vaccines for emergency approval, said the CDC study was overall “good news” .

However, he said he feared people would now think a dose of the vaccines was “good enough” and would not return for a second shot. He said studies have shown that immunity actually appears to be “more permanent” after the second dose, meaning protection may last longer.

“The reason these are two-dose vaccines is because the second dose provides a titer of neutralizing antibodies, virus-specific neutralizing antibodies, that is nearly ten times greater than the first dose,” he told CNBC. Neutralizing antibodies play an important role in the defense of cells against the virus.

Second, and more importantly, scientists have also discovered what are known as T cells, another important part of the immune response that usually lasts longer Immunity, he said.

There are also still questions about the highly contagious variants and whether the vaccines protect mild to moderate forms of the disease, he said.

Of the 3,950 participants in the study, 2,479, or 62.8%, received both recommended doses, and 477, or 12.1%, received only one dose, according to the CDC. The infection rate among the vaccinated participants was 0.04 compared to 1.38 among the non-vaccinated participants.

The study was conducted in eight locations in the United States: Phoenix, Tucson, and other areas in Arizona; Miami, Florida; Duluth, Minnesota; Portland, Oregon; Temple, Texas; and Salt Lake City, Utah. The majority of the participants were female, white, and had no chronic illnesses, according to the CDC.

The study had limitations, the CDC said, adding that delays in deliveries could reduce virus detection sensitivity of Covid-19 tests.

Preliminary real-world vaccine efficacy results for both vaccines complement and expand on estimates of vaccine efficacy from other recent studies, the CDC said. A large study published in the New England Journal of Medicine in February found that Pfizer’s vaccine was 94% effective against symptomatic Covid.

Categories
Health

Research Counsel Folks Who Had Covid-19 Ought to Get Single Vaccine Dose

Almost 30 million people in the United States – and likely many others whose diseases have never been diagnosed – have been infected with the coronavirus to date. Should these people still be vaccinated?

Two new studies answer this question with an emphatic yes.

In fact, research suggests that for these people, just one dose of the vaccine is enough to charge their antibodies and destroy the coronavirus – and even some other infectious variants.

The results of these new studies are consistent with the results of two others published in the past few weeks. Taken together, the research suggests that people who have had Covid-19 should be immunized – but a single dose of the vaccine may be enough.

“I think it’s a really strong rationale for why people who were previously infected with Covid should get the vaccine,” said Jennifer Gommerman, an immunologist at the University of Toronto who was not involved in the new research.

A person’s immune response to a natural infection varies widely. Most people make plenty of antibodies that last for many months. However, some people who have had mild or no symptoms of Covid-19 produce few antibodies that quickly drop to undetectable levels.

The vaccines “even hit the pitch,” said Dr. Gommerman, so that anyone who has recovered from Covid-19 will make enough antibodies to protect against the virus.

The latest study, which has not yet been published in a scientific journal, analyzed blood samples from people with Covid-19. The results suggest that her immune system would have problems fighting off B.1.351, the coronavirus variant first identified in South Africa.

But a shot of the Pfizer BioNTech or Moderna vaccine changed the picture dramatically: It increased the amount of antibodies in her blood by a thousand times – “a massive, massive surge,” said Andrew T. McGuire, immunologist at Fred Hutchinson Cancer Research Center in Seattle, who led the study.

Rinsed with antibodies, samples from all participants were able to neutralize not only B.1.351, but also the coronavirus that caused the SARS epidemic in 2003.

In fact, the antibodies appeared to work better than those in people who did not have Covid and had received two doses of a vaccine. Several studies have shown that the Pfizer-BioNTech and Moderna vaccines are about five times less effective against the variant.

The researchers received blood samples from 10 volunteers in the Seattle Covid Cohort Study who were vaccinated months after contracting the coronavirus. Seven of the participants received the Pfizer BioNTech vaccine and three received the Moderna vaccine.

Blood taken about two to three weeks after vaccination showed a significant increase in antibody levels compared to the samples taken before vaccination. The researchers don’t yet know how long the increased levels of antibodies will last, but “hopefully they will last,” said Dr. McGuire.

The researchers also saw a surge in immune cells remembering and fighting the virus, said Dr. McGuire. “It looks pretty clear that we are boosting their pre-existing immunity,” he said.

In another new study, New York University researchers found that a second dose of the vaccine was of no great benefit at all for people with Covid-19 – a phenomenon that has also been seen with vaccines against other viruses.

In this study, most people had been infected with the coronavirus eight or nine months previously, but their antibodies increased hundreds to a thousand times with the first dose of a vaccine. However, after the second dose, the antibody levels did not rise any further.

“It is real evidence of the strength of immunological memory that they are given a single dose and have a huge increase,” said Dr. Mark J. Mulligan, director of the NYU Langone Vaccine Center and lead author of the study.

In some parts of the world, including the United States, a significant minority of the population is already infected, noted Dr. Mulligan firmly. “You should definitely be vaccinated,” he said.

It is unclear whether the thousand-fold increase in antibody levels recorded in the laboratory will occur in real-world environments. However, research shows that a single shot is enough to significantly raise antibody levels, said Florian Krammer, an immunologist at the Icahn School of Medicine on Mount Sinai in New York.

Dr. Krammer led another of the new studies that showed that people who had Covid-19 and received a dose of vaccine had more serious side effects from the vaccination and had more antibodies than those who had not been infected before.

“When you put all four papers together, you get pretty good information about people who have had an infection and only need one vaccination,” said Dr. Krammer.

He and other researchers are trying to convince scientists from the Centers for Disease Control and Prevention to recommend only one dose for those who have recovered from Covid-19.

Ideally, these people should be monitored after the first shot in case their antibody levels drop after a few weeks or months, said Dennis R. Burton, an immunologist at the Scripps Research Institute in La Jolla, California.

The fact that the charged antibodies seen in the new study can fight the 2003 SARS virus suggests that a single dose of the vaccine may have induced the volunteer’s bodies to produce “largely neutralizing antibodies” – immune molecules that are able to target a wide range of related antibodies to viruses, said Dr. Burton.

He and other scientists have spent decades investigating whether largely neutralizing antibodies can fight multiple versions of HIV at the same time. HIV mutates faster than any other virus and evades most antibodies quickly.

The new coronavirus is mutating much more slowly, but there are now several variants of the virus that appear to have become more contagious or which are thwarting the immune system. The new study could provide clues on how to make a single vaccine that stimulates the production of largely neutralizing antibodies that can destroy all variants of the coronavirus, said Dr. Burton.

Without such a vaccine, scientists would have to adjust the vaccines every time the virus changes significantly. “You’re kind of a whac-a-mole approach,” he said. It will likely take many months, if not more, to develop and test this type of vaccine against the coronavirus, but “this is the longer term way to approach this virus.”

Categories
Health

Folks Who Have Had Covid Ought to Get Single Vaccine Dose, Research Recommend

Almost 30 million people in the United States – and likely many others whose diseases have never been diagnosed – have been infected with the coronavirus to date. Should these people still be vaccinated?

Two new studies answer this question with an emphatic yes.

In fact, research suggests that for these people, just one dose of the vaccine is enough to charge their antibodies and destroy the coronavirus – and even some other infectious variants.

The results of these new studies are consistent with the results of two others published in the past few weeks. Taken together, the research suggests that people who have had Covid-19 should be immunized – but a single dose of the vaccine may be enough.

“I think it’s a really strong rationale for why people who were previously infected with Covid should get the vaccine,” said Jennifer Gommerman, an immunologist at the University of Toronto who was not involved in the new research.

A person’s immune response to a natural infection varies widely. Most people make plenty of antibodies that last for many months. However, some people who have had mild or no symptoms of Covid-19 produce few antibodies that quickly drop to undetectable levels.

The vaccines “even hit the pitch,” said Dr. Gommerman, so that anyone who has recovered from Covid-19 will make enough antibodies to protect against the virus.

The latest study, which has not yet been published in a scientific journal, analyzed blood samples from people with Covid-19. The results suggest that her immune system would have problems fighting off B.1.351, the coronavirus variant first identified in South Africa.

But a shot of the Pfizer BioNTech or Moderna vaccine changed the picture dramatically: It increased the amount of antibodies in her blood by a thousand times – “a massive, massive surge,” said Andrew T. McGuire, immunologist at Fred Hutchinson Cancer Research Center in Seattle, who led the study.

Rinsed with antibodies, samples from all participants were able to neutralize not only B.1.351, but also the coronavirus that caused the SARS epidemic in 2003.

In fact, the antibodies appeared to work better than those in people who did not have Covid and had received two doses of a vaccine. Several studies have shown that the Pfizer-BioNTech and Moderna vaccines are about five times less effective against the variant.

The researchers received blood samples from 10 volunteers in the Seattle Covid Cohort Study who were vaccinated months after contracting the coronavirus. Seven of the participants received the Pfizer BioNTech vaccine and three received the Moderna vaccine.

Blood taken about two to three weeks after vaccination showed a significant increase in antibody levels compared to the samples taken before vaccination. The researchers don’t yet know how long the increased levels of antibodies will last, but “hopefully they will last,” said Dr. McGuire.

Updated

Apr. 19, 2021 at 12:01 am ET

The researchers also saw a surge in immune cells remembering and fighting the virus, said Dr. McGuire. “It looks pretty clear that we are boosting their pre-existing immunity,” he said.

In another new study, New York University researchers found that a second dose of the vaccine was of no great benefit at all for people with Covid-19 – a phenomenon that has also been seen with vaccines against other viruses.

In this study, most people had been infected with the coronavirus eight or nine months previously, but their antibodies increased hundreds to a thousand times with the first dose of a vaccine. However, after the second dose, the antibody levels did not rise any further.

“It is real evidence of the strength of immunological memory that they are given a single dose and have a huge increase,” said Dr. Mark J. Mulligan, director of the NYU Langone Vaccine Center and lead author of the study.

In some parts of the world, including the United States, a significant minority of the population is already infected, noted Dr. Mulligan firmly. “You should definitely be vaccinated,” he said.

It is unclear whether the thousand-fold increase in antibody levels recorded in the laboratory will occur in real-world environments. However, research shows that a single shot is enough to significantly raise antibody levels, said Florian Krammer, an immunologist at the Icahn School of Medicine on Mount Sinai in New York.

Dr. Krammer led another of the new studies that showed that people who had Covid-19 and received a dose of vaccine had more serious side effects from the vaccination and had more antibodies than those who had not been infected before.

“When you put all four papers together, you get pretty good information about people who have had an infection and only need one vaccination,” said Dr. Krammer.

He and other researchers are trying to convince scientists from the Centers for Disease Control and Prevention to recommend only one dose for those who have recovered from Covid-19.

Ideally, these people should be monitored after the first shot in case their antibody levels drop after a few weeks or months, said Dennis R. Burton, an immunologist at the Scripps Research Institute in La Jolla, California.

The fact that the charged antibodies seen in the new study can fight the 2003 SARS virus suggests that a single dose of the vaccine may have induced the volunteer’s bodies to produce “largely neutralizing antibodies” – immune molecules that are able to target a wide range of related antibodies to viruses, said Dr. Burton.

He and other scientists have spent decades investigating whether largely neutralizing antibodies can fight multiple versions of HIV at the same time. HIV mutates faster than any other virus and evades most antibodies quickly.

The new coronavirus is mutating much more slowly, but there are now several variants of the virus that appear to have become more contagious or which are thwarting the immune system. The new study could provide clues on how to make a single vaccine that stimulates the production of largely neutralizing antibodies that can destroy all variants of the coronavirus, said Dr. Burton.

Without such a vaccine, scientists would have to adjust the vaccines every time the virus changes significantly. “You’re kind of a whac-a-mole approach,” he said. It will likely take many months, if not more, to develop and test this type of vaccine against the coronavirus, but “this is the longer term way to approach this virus.”

Categories
Health

May a Single Vaccine Work In opposition to All Coronaviruses?

The invention of the Covid-19 vaccine will be remembered as a milestone in the history of medicine, creating in a few months what had previously taken up to a decade. Dr. However, Kayvon Modjarrad, director of the Emerging Infectious Disease Division at the Walter Reed Army Institute of Research in Silver Springs, Md., Is not satisfied.

“It’s not fast enough,” he said. More than 2.3 million people around the world have died, and many countries won’t have full access to the vaccines for a year or two: “Fast – really fast – got it on the first day there.”

There will be more coronavirus outbreaks in the future. Bats and other mammals abound in strains and species of this abundance Family of viruses. Some of these pathogens will inevitably cross the species barrier and cause new pandemics. It’s only a matter of time.

Dr. Modjarrad is one of many scientists who has been calling for a different type of vaccine for years: one that can work against all coronaviruses. These calls were largely ignored until Covid-19 showed how catastrophic coronaviruses can be.

Now researchers are starting to develop prototypes of what is known as a pancoronavirus vaccine, some of which show promise, albeit early. Results of animal experiments. Dr. Eric Topol, professor of molecular medicine at the Scripps Research Institute in San Diego, believes scientists should team up immediately on another major vaccine-making project.

“We have to find real workers to accelerate this so we can have it this year,” he said. Dr. Topol and Dennis Burton, a Scripps immunologist, called for this project on comprehensive coronavirus vaccines in Nature magazine Monday.

After coronaviruses were first identified in the 1960s, they weren’t a high priority for vaccine manufacturers. For decades, it seemed like they caused only mild colds. However, in 2002, a new coronavirus called SARS-CoV emerged, causing fatal pneumonia called SARS (Severe Acute Respiratory Syndrome). Scientists have been trying to make a vaccine for it.

Since no one had made a coronavirus vaccine for humans before, there was a lot to learn about its biology. Ultimately, the researchers chose a target for immunity: a protein on the surface of the virus called a spike. Antibodies sticking to the tip can prevent the coronavirus from entering cells and stop infection.

However, public health officials in Asia and elsewhere did not wait for the invention of a SARS vaccine to come to work. Their quarantines and other efforts have proven remarkably effective. Within a few months, they wiped out SARS-CoV with only 774 deaths.

The threat from coronavirus became even more apparent in 2012 when a second type of bat overflowed and caused another deadly respiratory disease called MERS. The researchers started working on MERS vaccines. However, some researchers wondered whether making a new vaccine for each new coronavirus – which Dr. Modjarrad called “One Bug, One Drug Approach” – the smartest strategy was. Wouldn’t it be better, they thought, if a single vaccine could work against SARS, MERS, and any other coronavirus?

That idea went nowhere for years. MERS and SARS caused relatively few deaths and were soon dwarfed by outbreaks of other viruses such as Ebola and Zika.

In 2016, Maria Elena Bottazzi, a virologist at Baylor College of Medicine, and her colleagues applied for assistance from the American government to develop a pancoronavirus vaccine, but were not given it. “They said there was no interest in pancorona,” recalled Dr. Bottazzi.

Their team even lost funding to develop a SARS vaccine after showing that it works in mice, is non-toxic to human cells, and can be manufactured on a large scale. A coronavirus that had disappeared from view just wasn’t a top priority.

Without enough money to start clinical trials, the scientists stored their SARS vaccine in a freezer and moved on to other research. “It was a fight,” said Dr. Bottazzi.

Dr. Matthew Memoli, a virologist at the National Institute for Allergies and Infectious Diseases, views these decisions as a huge mistake. “It’s a failure of our science system,” he said. “Funders tend to chase after shiny objects.”

Three years later, a third dangerous coronavirus emerged: the SARS-CoV-2 strain that causes Covid-19. Although this virus has a much lower death rate than its cousins ​​that cause SARS and MERS, it spreads far better from person to person, resulting in and still increasing in more than 106 million documented cases around the world.

Updated

Apr. 9, 2021, 4:25 p.m. ET

All of the lessons researchers learned about coronaviruses helped them quickly manufacture new vaccines for SARS-CoV-2. Dr. Bottazzi and her colleagues used the technology they developed to make SARS vaccines to make one for Covid-19, which is currently in early clinical trials.

Other researchers used even newer methods to move faster. The German company BioNTech has developed a genetic molecule called messenger RNA that codes for the spike protein. Working with Pfizer, the companies received US government approval for their vaccine in just 11 months. The previous record for a vaccine against chickenpox was four years.

Although the Covid-19 pandemic is far from over, a number of researchers are calling for preparations for the next deadly coronavirus.

“It’s happened three times,” said Daniel Hoft, a virologist at Saint Louis University. “It will most likely happen again.”

Researchers at VBI Vaccines, a Cambridge-based company, took a small step towards a pancoronavirus vaccine last summer. They created virus-like shells that were studded with spike proteins from the three coronaviruses that caused SARS, MERS and Covid-19.

When the researchers injected this three-spike vaccine into mice, the animals made antibodies that were effective against all three coronaviruses. Interestingly, some of these antibodies could also bind to a fourth human coronavirus that causes seasonal colds – although the spike proteins from this virus were not in the vaccine. The scientists have published this data, but have not yet published it in a scientific journal.

David Anderson, chief scientist for the VBI, said it was not clear why the vaccine worked this way. One possibility is that an immune cell that is presented with multiple versions of a protein at the same time will not make antibodies against just one. Instead, a compromise antibody is made that works against all.

“You train it,” said Dr. Anderson, although he warned that this was speculation for now.

Last month, Pamela Bjorkman, a structural biologist at Caltech, and her colleagues published a more in-depth experiment with a universal coronavirus vaccine in Science magazine. The researchers only attached the tips of spike proteins from eight different coronaviruses to a protein core known as nanoparticles. After injecting these nanoparticles into mice, the animals produced antibodies that could attach to all eight coronaviruses – and to four other coronaviruses that the scientists hadn’t used in the vaccine.

Dr. Modjarrad leads a team at Walter Reed that is developing another vaccine based on a nanoparticle filled with protein fragments. They expect to begin clinical trials on volunteers next month. Although the vaccine currently only uses protein fragments from SARS-CoV-2 spikes, Dr. Modjarrad and his colleagues are preparing to convert it as a pancoronavirus vaccine.

Dr. Hoft at Saint Louis University is working on a universal vaccine that does not rely on antibodies to the spike protein. Working with Gritstone Oncology, a California-based biotech company, he developed a vaccine that prompts cells to make surface proteins that could alert the immune system as if a coronavirus – any coronavirus – was present. They are currently preparing a clinical trial to determine if it will be effective against SARS-CoV-2.

“We are interested in developing a third generation vaccine that is on the shelf and ready for the future outbreak,” said Dr. Court.

Dr. Topol believes that scientists should investigate another strategy as well: looking for the pancoronavirus antibodies that our own bodies make during infections.

Researchers studying HIV and other viruses have discovered rare types that act against a variety of related strains amid the billions of antibodies produced during infection. It might be possible to develop vaccines that will induce the body to make plenty of these largely neutralizing antibodies.

Coronaviruses are similar enough to each other, said Dr. Topol that it may not be that difficult to develop vaccines that make largely neutralizing antibodies. “This is an easy-to-remove family of viruses,” he said.

Finding a pancoronavirus vaccine may take longer than Dr. Topol’s sunny expectations. But even if it took a few years, it could help prepare the world for the next coronavirus to cross species boundary.

“I think we can have vaccines to prevent such pandemics,” said Dr. Memoli. “None of us want to go through that again. And we don’t want our children to go through this again, or our grandchildren or our descendants in 100 years. “

Categories
Health

Single within the Pandemic: Coronavirus and Hooking Up

Anna, who is 29 and being asked to be identified by her middle name to protect her high-profile Washington, DC job, said the pandemic had put her under pressure. “When people my age aren’t married, they’re getting serious – about marriage, about children,” she said. “For people together, their schedules are speeding up because the pandemic is forcing them to make decisions. While single people cannot return in that year of their life. “

In August, she flew to Chicago to meet a man she’d texted and spoken to on FaceTime for a month. “You need the physical meeting,” she said. “I don’t even say sex. You might decide that you hate someone for chewing that way. “

The two spent a weekend in a hotel. “He was the only person I was familiar with for 10 months,” said Anna. She said she wouldn’t want to meet a stranger in person on a dating app. In this case, she knew where her date was working and that because of his work he had to undergo background checks and follow the strict security guidelines of Covid-19.

“It’s very difficult as an individual,” said Laura Khalil, 40, a Detroit podcast producer and host. Her parents who live nearby belong to a risk group and she is afraid of infecting them. “I couldn’t even touch my family,” said Ms. Khalil.

In August she decided to try again. After a few unsuccessful walks, she struck a match in a street cafe. They had a date as normal as a pandemic, with no mask, and after that, Ms. Khalil took a coronavirus test and was quarantined.

“I knew he was working from home, he had a capsule and he wasn’t going out,” she said. “Do I trust you? I believe you these are things we can’t know I can only accept and hope that you are not lying to me. “